Skip to Content

AbbVie Inc ABBV Stock Quote

| Rating as of


Last close prices updated as of Jun 09, 2023, 7:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 138.18
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Value
  • Day Range 137.08  –  139.19
  • Year Range 131.10  –  168.11
  • Market Cap 243.7895 Bil
  • Volume / Avg 10.0 /  5.9 Mil
  • Price / Sales 4.33
  • Price / Book 18.37
  • Forward Div Yield 4.28%
  • Trailing Div Yield 4.18%

Morningstar‘s Stock Analysis ABBV

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Despite Humira Biosimilar Headwinds, AbbVie's Strong Portfolio Should Support Steady Earnings

Damien Conover Sector Director

Business Strategy and Outlook

| Damien Conover |

While AbbVie holds a strong portfolio of marketed and pipeline drugs, the increasing competition to the company's key drug Humira should slow the growth for the company. At close to 40% of total sales and a higher portion of earnings (due to higher margin revenue), Humira is a key determinant of AbbVie's earnings performance over the next three years.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ABBV

Company Profile ABBV

Business Description

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

1 North Waukegan Road
North Chicago, IL, 60064-6400
Industry Drug Manufacturers - General
Employees 50,000

Related Articles ABBV

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of ABBV’s competitive advantage.

AbbVie Inc


Eli Lilly and Co


Johnson & Johnson


Merck & Co Inc

+$0.54 (0.39%) +$0.38 (0.09%) −$0.25 (0.16%) +$0.39 (0.35%)
Market Cap
243.79 Bil423.41 Bil415.82 Bil280.92 Bil
Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for AbbVie Inc Stock

Yes. ABBV has a forward dividend yield of 4.28%. See ABBV’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ABBV’s market cap is 243.79 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ABBV’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ABBV’s price/sales is 4.33.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

ABBV’s price/forward earnings is 32.59.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

ABBV’s price/book is 18.36.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See ABBV’s valuation ratios compared to the Market Index.

ABBV’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ABBV’s historical performance against its industry peers and the overall market.